Study of Cabozantinib in Combination With Nivolumab and Ipilimumab in Patients With Previously Untreated Advanced or Metastatic Renal Cell Carcinoma (NCT03937219)
A Randomized, Double-Blind, Controlled Phase 3 Study of Cabozantinib in Combination With Nivolumab and Ipilimumab Versus Nivolumab and Ipilimumab in Subjects With Previously Untreated Advanced or Metastatic Renal Cell Carcinoma of Intermediate or Poor Risk
🩺 Plain-English Summary (8th-Grade Level)
This is a multicenter, randomized, double-blinded, controlled Phase 3 trial of cabozantinib in combination with nivolumab and ipilimumab versus nivolumab and ipilimumab in combination with matched placebo. Approximately 840 eligible subjects with intermediate- or poor-risk advanced or metastatic RCC by IMDC criteria will be randomized in a 1:1 ratio at approximately 180 sites.
Who can join: Review the eligibility criteria below.
Location: Exelixis Clinical Site #116 — La Jolla, California
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (159 Sites)
Showing the first 25 of 159 sites.
- Exelixis Clinical Site #116 — La Jolla, California
- Exelixis Clinical Site #166 — Orange, California
- Exelixis Clinical Site #29 — Boca Raton, Florida
- Exelixis Clinical Site #44 — Miami, Florida
- Exelixis Clinical Site #3 — Atlanta, Georgia
- Exelixis Clinical Site #95 — Chicago, Illinois
- Exelixis Clinical Site #69 — Scarborough, Maine
- Exelixis Clinical Site #58A — Baltimore, Maryland
- Exelixis Clinical Site #7B — Boston, Massachusetts
- Exelixis Clinical Site #7A — Boston, Massachusetts
- Exelixis Clinical Site #7C — Boston, Massachusetts
- Exelixis Clinical Site #6 — Burlington, Massachusetts
- Exelixis Clinical Site #15 — Detroit, Michigan
- Exelixis Clinical Site #24 — Kansas City, Missouri
- Exelixis Clinical Site #4 — St Louis, Missouri
- Exelixis Clinical Site #2 — Omaha, Nebraska
- Exelixis Clinical Site #159 — New York, New York
- Exelixis Clinical Site #8 — New York, New York
- Exelixis Clinical Site #19 — Syracuse, New York
- Exelixis Clinical Site #101 — Charlotte, North Carolina
- Exelixis Clinical Site #107 — Portland, Oregon
- Exelixis Clinical Site #12 — Pittsburgh, Pennsylvania
- Exelixis Clinical Site #102 — Charleston, South Carolina
- Exelixis Clinical Site #5 — Myrtle Beach, South Carolina
- Exelixis Clinical Site #10 — Nashville, Tennessee
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Renal Cell Carcinoma
- A Study of Immune Checkpoint Inhibitor Combinations With Axitinib in Participants With Untreated Locally Advanced Unresectable or Metastatic Renal Cell Carcinoma — Birmingham, Alabama
- 89Zr-DFO-Atezolizumab ImmunoPET/CT in Patients With Locally Advanced or Metastatic Renal Cell Carcinoma — Dallas, Texas
- Lenvatinib/Everolimus or Lenvatinib/Pembrolizumab Versus Sunitinib Alone as Treatment of Advanced Renal Cell Carcinoma — Stanford, California
- Follow-up After Metastasectomy in Patients With Kidney Cancer — Houston, Texas
- A Study of HFB200603 as a Single Agent and in Combination With Tislelizumab in Adult Patients With Advanced Solid Tumors — Los Angeles, California
Explore by condition: All Renal Cell Carcinoma clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.